Comment on “Individualized Prognostication Based on Deep‐Learning Models Using Computed Tomography as an Imaging Biomarker After Hepatocellular Carcinoma Resection”

Bibliographic Details
Main Authors:	Minghai Shen, Huihui Shen
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Hepatology Research
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Individualized Prognostication Based on Deep‐Learning Models Using Computed Tomography as an Imaging Biomarker After Hepatocellular Carcinoma Resection
by: Hiroji Shinkawa, et al.
Published: (2025)

Utility of Oncological Resectability Criteria in Recurrent Hepatocellular Carcinoma After Hepatectomy
by: Nobuaki Ishihara, et al.
Published: (2025)

Clinical Impact of Recurrence Beyond the Milan Criteria After Curative Resection of Hepatocellular Carcinoma
by: Takeshi Terashima, et al.
Published: (2025)

Significance of Evaluating Tumor Markers in the Oncological Criteria for Resectability in Hepatocellular Carcinoma
by: Yuya Miura, et al.
Published: (2025)

Mitochondrial Oxidative Stress in Circulating Leukocytes as a Prognostic Marker in Hepatocellular Carcinoma
by: Víctor Merino, et al.
Published: (2025)

Lymphocyte‐to‐Monocyte Ratio as a Practical Biomarker for Immunotherapy Response in Hepatocellular Carcinoma
by: Satoshi Tanaka
Published: (2025)

Impact of Surgical Resection on Hepatocellular Carcinoma Following Systemic Drug Therapy: A Multicenter Retrospective Observational Study
by: Takamichi Ishii, et al.
Published: (2025)

Surgical Resections for Hepatocellular Carcinomas Arising From Fontan‐Associated Liver Disease; Open, Laparoscopic and Robotic Hepatectomies
by: Takashi Motomura, et al.
Published: (2026)

Adjuvant Transarterial Chemoembolization After Truly Curative Resection Does Not Improve Survival of Patients With Hepatocellular Carcinoma at High Risk of Recurrence: A Target Trial Emulation Study
by: Jia‐Yong Su, et al.
Published: (2025)

Refining Surgical Candidate Selection After Systemic Therapy in Advanced Hepatocellular Carcinoma
by: Jinzhen Huang, et al.
Published: (2025)

Prognostic Value of PALBI in Patients With Hepatocellular Carcinoma and Concurrent Chronic Kidney Disease: A Nomogram Development
by: Jihye Lim, et al.
Published: (2026)

Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma
by: Kazuya Kariyama, et al.
Published: (2026)

Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
by: Tomomitsu Matono, et al.
Published: (2025)

A Novel Diagnostic Approach for Hepatocellular Carcinoma Using Glycosylated Ferritin
by: Akiyo Ishiguro, et al.
Published: (2026)

Dynamic Early Survival Prediction Model for Hepatocellular Carcinoma Patients Treated With Atezolizumab and Bevacizumab: A Longitudinal Deep Learning Analysis
by: Weiming Li, et al.
Published: (2025)

The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy
by: Van Khanh Nguyen, et al.
Published: (2026)

Tumor Mutational Concordance and Recurrence Timing in Hepatocellular Carcinoma
by: Yuya Miura, et al.
Published: (2026)

Comment on “Effect of Direct‐Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan”
by: Haonan Jin
Published: (2026)

The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long‐Term Administration of Nucleos(t)ide Analogs
by: Kazuhiro Murai, et al.
Published: (2025)

Validation of Liquid Biopsy Using a Methylated SEPT9 Assay and Integrated Index for Detecting Hepatocellular Carcinoma
by: Issei Saeki, et al.
Published: (2025)

Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma
by: Yuichiro Suzuki, et al.
Published: (2025)

Subcutaneous Adipose Tissue Accumulation is Associated With an Improved Prognosis in Patients With Hepatocellular Carcinoma
by: Kenji Imai, et al.
Published: (2026)

Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study
by: Teiji Kuzuya, et al.
Published: (2025)

Prospective Study of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Based on Hepatobiliary Phase of Gd‐EOB‐DTPA‐MRI
by: Tomoko Aoki, et al.
Published: (2026)

Toward a Synthetic Data Revolution: Diffusion Model‐Enhanced Hepatocellular Carcinoma Prediction in Steatotic Liver Disease
by: Masaya Sato, et al.
Published: (2026)

Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma
by: Kenji Imai, et al.
Published: (2025)

Dual Escape From Disulfidptosis and Ferroptosis Drives Highly Aggressive, Hypermetabolic Hepatocellular Carcinoma
by: Junya Mita, et al.
Published: (2026)

Enhancing Robustness in Prognostic Biomarker Research: A Letter on Validating Model Assumptions and Handling Zero Events
by: Haiying Hu, et al.
Published: (2025)

Differential Eligibility for Immune Checkpoint Inhibitor‐Based Therapy at Recurrence: A Potential Explanation for Improved Survival in Viral Hepatocellular Carcinoma
by: Kazuya Kariyama, et al.
Published: (2026)

Letter to the Editor: Pre‐Treatment Liver Stiffness Is a Stronger Predictor of Hepatocellular Carcinoma Development Than Post‐Treatment Liver Stiffness After Hepatitis C Virus Eradication
by: Chaofan Li, et al.
Published: (2025)

Response to “Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma”
by: Kenji Imai, et al.
Published: (2026)

Letter to the Editor: “Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma”
by: Lixia Yao, et al.
Published: (2025)

Response to “Letter to the Editor: Pre‐Treatment Liver Stiffness is a Stronger Predictor of Hepatocellular Carcinoma Development Than Post‐Treatment Liver Stiffness After Hepatitis C Virus Eradication”
by: Takuma Nakatsuka, et al.
Published: (2025)

Bradycardic Responses During Thermal Ablation for Hepatocellular Carcinoma: Impact of Procedural Pain Severity and Autonomic Imbalance
by: Yasuyuki Komiyama, et al.
Published: (2025)

Dual Escape From Ferroptosis and Disulfidptosis Denotes a Hypermetabolic, High‐Risk Subtype of Hepatocellular Carcinoma
by: Tadashi Namisaki, et al.
Published: (2026)

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
by: Keishi Ouchi, et al.
Published: (2026)

Effect of Direct‐Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan
by: Hironori Ochi, et al.
Published: (2026)

Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early‐Stage Viral Disease
by: Kazuya Kariyama, et al.
Published: (2025)

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab
by: Kazunari Tanaka, et al.
Published: (2026)

Microwave Thermosphere Ablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma: Optimizing Treatment Strategies for Tumor Size and Malignancy Grade
by: Hideyuki Tamai, et al.
Published: (2025)

Similar Items

Similar Items